A phase 1/2 multicenter trial (EVOLVE, NCT03430011) is investigating the safety and efficacy of JCARH125 in patients with high R/R MM, who have received ≥ 3 prior regimens, including ASCT, a PI, IMiD, and an anti-CD38 mAb, unless not a candidate. This evidence concerns the gene CD38 and Miyoshi myopathy.